Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)
T. Pascual1, A. Fernandez-Martinez1, M. Tanioka1, M.V. Dieci2, S. Pernas Simon3, J. Gavila Gregori4, V. Guarneri5, J. Cortés6, P. Villagrasa7, M.J. Vidal8, B. Adamo8, M. Muñoz8, G. Griguolo9, A. Llombart Cussac10, A.M. Antunes De Melo e Oliveira11, L. Paré7, L.A. Carey12, C.M. Perou1, A. Prat8
Comunicaciones en congresos
ePoster
ESMO BREAST
2020
